Last reviewed 2026-05-15 · How we verify

GC4711 Oral Capsule G-119

Galera Therapeutics, Inc. · Phase 1 active Small molecule

GC4711 Oral Capsule G-119 is a Small molecule drug developed by Galera Therapeutics, Inc.. It is currently in Phase 1 development.

At a glance

Generic name	GC4711 Oral Capsule G-119
Sponsor	Galera Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 1 Study of the Safety and Pharmacokinetics of GC4711 (Oral Capsule) Compared to GC4419 (IV Infusion) and GC4711 (IV Infusion) in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GC4711 Oral Capsule G-119 CI brief — competitive landscape report
GC4711 Oral Capsule G-119 updates RSS · CI watch RSS
Galera Therapeutics, Inc. portfolio CI

Frequently asked questions about GC4711 Oral Capsule G-119

What is GC4711 Oral Capsule G-119?

GC4711 Oral Capsule G-119 is a Small molecule drug developed by Galera Therapeutics, Inc..

Who makes GC4711 Oral Capsule G-119?

GC4711 Oral Capsule G-119 is developed by Galera Therapeutics, Inc. (see full Galera Therapeutics, Inc. pipeline at /company/galera-therapeutics-inc).

What development phase is GC4711 Oral Capsule G-119 in?

GC4711 Oral Capsule G-119 is in Phase 1.

Manufacturer: Galera Therapeutics, Inc. — full pipeline
Compare: GC4711 Oral Capsule G-119 vs similar drugs
Pricing: GC4711 Oral Capsule G-119 cost, discount & access